Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

[1] Walker WT(2010)Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine Expert Rev Vaccines 9 1385-1398

[2] Faust SN(2010)Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study BMJ 340 c2649-1745

[3] Waddington CS(2010)Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial Vaccine 28 1740-4361

[4] Walker WT(2011)Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents Vaccine 29 4353-273

[5] Oeser C(2010)An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers Vaccine 29 266-584

[6] Reiner A(2011)Clinical evaluation of an AS03- adjuvanted pandemic influenza H1N1 2009 vaccine in children (Preliminary report) J Jap Pediatr Soc 115 578-11

[7] John T(2012)Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 infl uenza vaccine Human Vaccines & Immunotherapeutics 8 1-1653

[8] Wilkins S(2010)Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults J Infect Dis 201 1644-2473

[9] Casey M(2011)Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity Vaccine 29 2461-138

[10] Eccleston PE(2004)Immunogenicity and protective efficacy of influenza vaccination Virus Res 103 133-394

[1] Walker WT(2010)Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine Expert Rev Vaccines 9 1385-1398

[2] Faust SN(2010)Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study BMJ 340 c2649-1745

[3] Waddington CS(2010)Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial Vaccine 28 1740-4361

[4] Walker WT(2011)Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents Vaccine 29 4353-273

[5] Oeser C(2010)An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers Vaccine 29 266-584

[6] Reiner A(2011)Clinical evaluation of an AS03- adjuvanted pandemic influenza H1N1 2009 vaccine in children (Preliminary report) J Jap Pediatr Soc 115 578-11

[7] John T(2012)Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 infl uenza vaccine Human Vaccines & Immunotherapeutics 8 1-1653

[8] Wilkins S(2010)Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults J Infect Dis 201 1644-2473

[9] Casey M(2011)Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity Vaccine 29 2461-138

[10] Eccleston PE(2004)Immunogenicity and protective efficacy of influenza vaccination Virus Res 103 133-394